Can a brain scan tailor TMS to quiet cigarette cravings?
NCT ID NCT07812753
First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time
Summary
Researchers are testing whether a personalized form of transcranial magnetic stimulation (TMS) changes reward-related brain activity more than standard TMS in adults who smoke cigarettes. Participants receive 15 TMS sessions over three weeks, with brain scans used to pick the stimulation target for the personalized group. The study measures brain waves linked to reward processing and self-reported cravings to see if the personalized approach reduces smoking more effectively.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- transcranial magnetic stimulation (TMS), a noninvasive brain stimulation technique
- What this could lead to
- If personalized TMS works better, it could offer a more effective way to help people cut down or quit smoking by targeting each person's brain circuitry.
- What could go wrong
- This is a small, early-stage study with 54 participants. TMS can cause scalp discomfort or headaches, and brain activity changes may not translate into lasting reductions in smoking.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 54 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2026
- Expected to finish
-
Jul 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Be between the ages of 18 and 60 years old * Smoke 10 or more cigarettes per day and have a carbon monoxide (CO) level greater than 10 ppm indicative of recent smoking * Have not received substance abuse treatment within the previous 30 days * Meet criteria for Tobacco Use Disorder as determined by the Mini International Neuropsychiatric Interview (MINI): meeting 4 or more of the 11 diagnostic symptoms of Tobacco Use Disorder within a 12-month period * If female, test non-pregnant * Show no evidence of focal or diffuse brain lesions on MRI * Be willing to provide informed consent * Be able to comply with protocol requirements and likely to complete all study procedures * Be motivated to quit smoking, based on a response of "very likely" or "somewhat likely" on the Motivation to Stop Scale (scores 4-7) Exclusion Criteria: * Meeting MINI diagnostic criteria for any non-tobacco substance use disorder other than Caffeine Use Disorder, Cannabis Use Disorder - Mild, or Alcohol Use Disorder - Mild (Mild defined as meeting 2 to 3 of the 11 diagnostic symptoms within a 12-month period) * Contraindications to MRI (e.g., metal in the skull, orbital, or intracranial cavity, or claustrophobia) * Contraindication to repetitive TMS * History of autoimmune, endocrine, viral, or vascular disorders affecting the brain * History or MRI evidence of a neurological disorder causing local or diffuse brain lesions or significant physical impairment * Unstable cardiac disease, uncontrolled hypertension, severe renal or liver insufficiency, or sleep apnea * Lifetime history of major Axis I disorders as confirmed by the MINI, including bipolar affective disorder, schizophrenia, post-traumatic stress disorder, suicidal ideation, or major depression * Current use of tobacco cessation pharmacotherapies, including nicotine patches, electronic cigarettes, gum, nasal spray, inhalers, nicotine lozenges, varenicline, or bupropion * Previous treatment with TMS
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Tobacco use disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Rutgers University Center for Molecular and Behavioral Neuroscience
RECRUITINGNewark, New Jersey, 07102, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Texts and wearables team up to help latinos quit smoking and get moving
- Can a WhatsApp message help smokers quit?
- Could a health Worker's support break the smoking habit in mental illness?
- Virtual reality could help new moms kick the habit
- Magnetic pulses aimed at the brain might help smokers with opioid addiction kick the habit
- Personalized nicotine patch dosing may boost quit rates